Immatics NV
IMTX
Company Profile
Business description
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
Contact
Paul-Ehrlich-Strasse 15
TubingenBW72076
DEUT: +49 707153970
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
407
Stocks News & Analysis
stocks
ASX top pick remains cheap despite weaker consumer confidence
Consumer caution dents growth, shares look cheap.
stocks
Chart of the Week: Aussie dividend yields below 10-year average
Income opportunities remain beneath the surface.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,098.10 | 107.10 | -1.16% |
| CAC 40 | 8,205.37 | 27.48 | 0.34% |
| DAX 40 | 26,325.01 | 112.66 | -0.43% |
| Dow JONES (US) | 51,523.06 | 1,833.06 | -3.44% |
| FTSE 100 | 10,782.66 | 46.55 | -0.43% |
| HKSE | 24,620.13 | 176.85 | -0.71% |
| NASDAQ | 24,315.00 | 1,421.52 | -5.52% |
| Nikkei 225 | 57,573.13 | 3,504.77 | -5.74% |
| NZX 50 Index | 13,991.87 | 99.10 | -0.70% |
| S&P 500 | 7,353.73 | 334.89 | -4.36% |
| S&P/ASX 200 | 8,972.30 | 92.80 | -1.02% |
| SSE Composite Index | 3,642.34 | 47.57 | -1.29% |